CPDC Announces Closure of Phase 3 Clinical Trial of [18F]PSMA-1007 Prostate Cancer Diagnostic Imaging Agent
Significant Milestone on the Path to Submission for Canadian Regulatory Approval in Late 2024 HAMILTON, ON, March 13, 2024 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development and commercialization of radiopharmaceuticals, today announced the closure of the Canadian Phase 3 trial for [18F]PSMA-1007. [18F]PSMA-1007 is a positron-emitting tomography … Read more